Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

Rich Eisen can’t bring himself to watch Stuart Scott ’30 for 30' yet
ESPN’s latest 30 for 30 documentary stays close to home, covering the life of Stuart Scott, an icon of the Worldwide Leader’s SportsCenter era. Rich...
Sun Feb 15, 2026

UNC business, nursing online programs rank among nation’s best
The 2026 U.S. News & World Report Best Online Program Rankings place online master’s programs from UNC Kenan-Flagler Business School and the UNC School of...
Sat Feb 14, 2026

Gift from UNC alums will fund 20 Carolina Covenant scholars
A transformational estate gift from Dwight Jacobs ’87 and Moira Jacobs ’87 will support future generations of Carolina Covenant scholars. “If we could help 20...
Mon Feb 9, 2026

Tar Heels revel in winter weather (again)
Coming off the heels of last weekend’s snow/sleet/ice mix, UNC received more wintry weather this weekend. This time Tar Heels had pure snow to enjoy...
Sun Feb 8, 2026